ライフサイエンスコーパス: A(2) receptor

1 .g., human platelet thrombin and thromboxane A2 receptors.

2 increase in Galphaq coupling to thromboxane A2 receptors.

3 n increase in ligand affinity of thromboxane A2 receptors.

4 tinguishable from human platelet thromboxane A2 receptors.

5 may mediate the desensitization of adenosine A2 receptors.

6 tent with the activation of ocular adenosine A2 receptors.

7 lly reversed by blockade of adenosine A1 and A2 receptors.

8 structural model for a GPCR, the thromboxane A(2) receptor.

9 is a homolog of the mammalian phospholipase A(2) receptor.

10 a phosphoproteins co-purify with thromboxane A(2) receptors.

11 podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-c

12 Phospholipase A2 receptor 1 (PLA2R) is a target autoantigen in 70% of

13 jor target antigen, the M-type phospholipase A2 receptor 1 (PLA2R).

14 the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently identified throm

15 ith autoantibodies against the phospholipase A2 receptor 1 (PLA2R1).

16 ) along with the major antigen phospholipase A2 receptor 1 (PLA2R1).

17 ntibodies targeting the M-type phospholipase A2 receptor-1 (PLA2R) on the surface of glomerular visce

18 the ortholog of the mammalian phospholipase A2 receptor, a mannose receptor family member, rather th

19 DPMA, an adenosine A2 receptor (A2R) agonist, decreased KDR mRNA in a dose-

20 imulatory concentrations; however, adenosine A2 receptor (A2R) agonists DPMA, NECA, and CGS21680 incr

21 5'-(N-ethylcalboxamido)-adenosine (adenosine A2 receptor [A2R] agonists, Kd = 15 and 16 nmol/l, respe

22 on of PKC can block the effects of adenosine A2 receptor activation by CGS-21680 on anoxia and reoxyg

23 A1 receptor activation, the implications of A2 receptor activation on synaptic transmission have not

24 d which inhibits neutrophil function through A2 receptor activation.

25 The A(2) receptor agonist 2-p-(2-carboxylethyl)-phenylamino-

26 The adenosine A(2) receptor agonist, CGS-21680, and DB-cAMP decreased

27 o-adenosine (NECA), a nonselective adenosine A(2) receptor agonist, or with 2-[p-(2-carboxyethyl)-phe

28 The adenosine A2 receptor agonist 5'-(N-cyclopropyl)-carboxamidoadenos

29 stimulated O2.- generation by the adenosine A2 receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA

30 The selective adenosine A2 receptor agonist DPMA (10 micromol/L) decreased TNF-a

31 an platelets by thrombin and the thromboxane A2 receptor agonist U46619 lead to phosphorylation of Ga

32 vasoconstriction induced by the thromboxane A2 receptor agonist U46619, which suggest a NO-independe

33 enosine (CGS-21680 [20 nmol/L], an adenosine A2 receptor agonist, R-(--)-N6-(2-phenylisopropyl)-adeno

34 ated by adenosine (10 microM, 2 min) and the A2-receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5

35 livers were treated with adenosine A(1) and A(2) receptor agonists or dibutyryl-cyclic adenosine mon

36 13) (of the G(12) family) by the thromboxane A(2) receptor alpha (TPalpha), via agonist-effected [(35

37 ne granular co-localization of Phospholipase A(2) receptor and IgG evident on transplant biopsy on da

38 The effect appears to be mediated by the A2 receptor and transduced through a G protein-adenylyl

39 demonstrated expression of the phospholipase A2 receptor and two G-protein-coupled receptors for LPC

40 y requires adenosine activation of adenosine A2 receptors and is mediated by beta gamma dimers.

41 acting to increase O2 delivery via adenosine A2 receptors and to decrease metabolic rate via A1 recep

42 8-cyclopentyltheophylline (CPT), but not the A(2) receptor antagonist 3, 7-dimethyl-1-propargylxanthi

43 In contrast, a highly specific A2 receptor antagonist (10(-7) or 10(-5) M) had no effec

44 yl-1, 3-dipropylxanthine (DPCPX) but not the A2 receptor antagonist 3, 7-dimethyl-1-propargylxanthine

45 or inhibition of adenosine by the adenosine A2 receptor antagonist 3,7-dimethyl-1-propargylxanthine

46 nists and AP-5 were reversed by an adenosine A2 receptor antagonist administered intraperitoneally.

47 lished by administration of the adenosine A1/A2 receptor antagonist PD 115,199 (3 mg/kg i.v.) before

48 Aspirin and the thromboxane A2 receptor antagonist SQ29548 inhibited activation of t

49 After pretreatment with the thromboxane A2 receptor antagonist SQ30, 741, the vasoconstrictor re

50 ected by 3,7-dimethy-1-propargylxanthine, an A2 receptor antagonist.

51 se of ticagrelor followed by an adenosine A1/A2-receptor antagonist [8-(p-sulfophenyl)theophylline, 4

52 ase, in the presence of the adenosine A1 and A2 receptor antagonists 8-cyclopentyl-1,3-dipropylxanthi

53 r agonist CGS-21680 (50% closure by day 2 in A2 receptor antagonists.

54 of L-arginine transport was inhibited by the A2-receptor antagonists ZM-241385 and 3,7-dimethyl-1-pro

55 hyl ester (an NO synthase inhibitor) and the A2-receptor antagonists ZM-241385 and DMPX prevented inc

56 circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic poly

57 P = 0.010] and those with anti-phospholipase A2 receptor antibodies [hazard ratio = 3.761 (1.635-8.65

58 Rates of antiphospholipase A2 receptor antibody (anti-PLA2R-Ab) depletion in NIAT-r

59 active against a polyclonal anti-thromboxane A2 receptor antibody.

60 riments tested the hypothesis that adenosine A2 receptors are involved in central reward function.

61 AMP increased phosphorylation of thromboxane A(2) receptor-associated Galpha(13) by 87 +/- 27%.

62 This is a very early case of Phospholipase A(2) receptor-associated recurrent membranous nephropath

63 isease is associated with anti-Phospholipase A(2) receptor autoantibodies.

64 rculating levels of serum anti-Phospholipase A(2) receptor autoantibody that declined over time in co

65 hropathy with circulating anti-Phospholipase A(2) receptor autoantibody, which supports the emerging

66 Adenosine A(2) receptor blockade prevented the protective effect o

67 A2 receptor blockade by the A2 antagonist, DMPX (3,7-dim

68 A2 receptor blockade in the presence of complete A1 rece

69 nase inhibition with aspirin and thromboxane A2 receptor blockade with ifetroban on the chronic vasod

70 D2 or adenosine A2 receptor blockade, pertussis toxin, Rp-cAMPS, or over

71 ling of Galpha(13) with platelet thromboxane A(2) receptors but destabilized coupling of Galpha(13) t

72 EP4, prostaglandin F2alpha, and thromboxane A2 receptors but not anti-inflammatory EP2, prostaglandi

73 onists, including caffeine, or targeting the A2 receptors by siRNA pretreatment of T cells improved t

74 uency test pulses (0.033 Hz) indicating that A2 receptors can enhance synaptic transmission.

75 Blockade of thromboxane A(2) receptor did not affect the serotonin response in a

76 elet aggregation via stimulation of platelet A(2) receptors) during brief I/R contributes to this imp

77 Agents active at A2 receptors either were without effect or could be bloc

78 The erythropoietin-producing hepatoma A2 receptor (EphA2) is a tyrosine kinase overexpressed b

79 The reduced form of the thromboxane A(2) receptor experienced a decrease in ligand binding a

80 nd activation of the signal molecules ephrin-A2 receptor, FAK, Src, and Rac1.

81 ntegrin molecules and tyrosine kinase ephrin-A2 receptor, followed by the activation of preexisting i

82 A2 receptors for extracellular adenosine might act as bo

83 mediates phosphorylation of the thromboxane A(2) receptor-G-protein complex.

84 y chromatography purification of thromboxane A(2) receptor-G-protein complexes from these membranes r

85 mammalian counterpart and is a phospholipase A(2) receptor homolog.

86 ate the presence of a functional thromboxane A2 receptor in oligodendrocytes and are consistent with

87 ons indicating a high density of thromboxane A2 receptors in myelinated brain and spinal cord fiber t

88 The presence of functional thromboxane A2 receptors in neonatal rat oligodendrocytes and human

89 The human platelet thromboxane A2 receptor is a member of the G-protein-coupled superfa

90 Together, these results suggest that the A2 receptors may play an important role in the induction

91 the protective effects of adenosine include A2-receptor mediated vasodilation, A1-receptor mediated

92 s, but the latter is dominant in thromboxane A(2) receptor-mediated contraction.

93 consequent suppression of slow AHPs, or (2) A(2)-receptor-mediated elevation of cAMP directly suppre

94 e considered two alternative hypotheses: (1) A(2)-receptor-mediated suppression of I(Ca) leading to s

95 y of the novel antagonist N-0861, the A1 and A2 receptor-mediated cardiac effects of adenosine were i

96 8-chlorostyrylcaffeine (CSC), suggesting an A2 receptor-mediated mechanism.

97 nstriction in vivo, which is often masked by A2 receptor-mediated vasodilation.

98 ine diminishes inflammation via occupancy of A2 receptors on inflammatory cells.

99 In conclusion, an adenosine A(2) receptor pathway coupled to increased cAMP mediates

100 Autoantibodies to the M-type phospholipase A(2) receptor (PLA(2)R) are sensitive and specific for i

101 The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in i

102 otein band detected the M-type phospholipase A(2) receptor (PLA(2)R).

103 The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-con

104 The characterization of the phospholipase A2 receptor (PLA2R) as the major target antigen in prima

105 Phospholipase A2 receptor (PLA2R) is a member of the mannose receptor

106 The M-type phospholipase A2 receptor (PLA2R) is expressed in podocytes in human g

107 Secretory phospholipase A2 receptor (PLA2R) is the target antigen of the auto-an

108 ht to determine the utility of phospholipase A2 receptor (PLA2R) staining for the detection of recurr

109 ve IgG4 autoantibodies against phospholipase A2 receptor (PLA2R).

110 ing IgG4 autoantibodies to the phospholipase A2 receptor (PLA2R).

111 ic variants in an HLA-DQA1 and phospholipase A2 receptor (PLA2R1) allele associate most significantly

112 The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopat

113 The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary

114 out the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein.

115 the physiological role of the phospholipase A2 receptor (PLA2R1).

116 We examined the role adenosine A2 receptors play in the efficacy of neurotransmission b

117 45 min following the tetanus indicating that A2 receptors play no significant role in the maintenance

118 racellular cAMP levels through activation of A2 receptors present on developing amacrine and ganglion

119 tion as the second intron of the thromboxane A2 receptor, prostaglandin D2 receptor, prostaglandin I2

120 The G(q)-coupled thromboxane A(2) receptor subtype, TPalpha, and G(i)-coupled TPbeta

121 he effects of adenosine and adenosine Al and A2 receptor subtype agonists on in vitro perfused contro

122 creases Galphaq association with thromboxane A2 receptors thereby shifting them to a higher affinity

123 probably mediated by activation of adenosine A2 receptors through the PKC pathway, and (3) the preser

124 from astrocytes by a direct effect on A1 and A2 receptors, thus providing a link between actions of N

125 HHV-8 uses langerin and the ephrin A2 receptor to infect Langerhans cells, which support fu

126 vasodilatation, and stimulates carotid body A2 receptors to increase respiration.

127 eased by acute hypoxia stimulates A1 but not A2 receptors to produce muscle vasodilatation, and stimu

128 Thromboxane A(2) receptor (TP receptor), a prostanoid receptor, belo

129 The thromboxane (TX) A(2) receptor (TP) encompasses two alternatively spliced

130 extracellular loop (eLP2) of the thromboxane A(2) receptor (TP) had been proposed to be involved in l

131 The thromboxane A(2) receptor (TP) is a G protein-coupled receptor that

132 Thromboxane synthase (TXAS) and thromboxane A(2) receptor (TP), two critical components for thrombox

133 F2alpha receptor (FP) (61), and thromboxane A2 receptor (TP) (11) while sparing EP2, EP3, and prosta

134 he PGF2 alpha receptor (FP), the thromboxane A2 receptor (TP) and the prostacyclin receptor (IP).

135 lexibility of the purified human thromboxane A2 receptor (TP) was characterized by spectroscopic appr

136 Human thromboxane A2 receptor (TP), a G protein-coupled receptor (GPCR), i

137 date the molecular mechanisms of thromboxane A2 receptor (TP)-induced insulin resistance in endotheli

138 Here, we show that vasopressive thromboxane A2 receptors (TP) can intimately couple with and inhibit

139 We explore here, using the thromboxane A2 receptor TPalpha, the ability of G12 and G13 to repor

140 tors; two splice variants of the thromboxane A2 receptor (TPalpha and TPbeta) have been cloned.

141 n of the signaling properties of thromboxane A2 receptor (TPalpha) -Galpha12 and -Galpha13 fusion con

142 g partner of the beta-isoform of thromboxane A2 receptor (TPbeta) by yeast two-hybrid screening.

143 Thromboxane A2 receptor (TPr) stimulation induces cellular hypertrop

144 tion, and functional coupling to thromboxane A(2) receptors (TPRs) during oligodendrocyte (OLG) devel

145 uced by arachidonic acid and the thromboxane A(2) receptor (TxA(2)R) agonist U46619 were reduced in P

146 oxidative stress, activates the thromboxane A2 receptor (TXAR) and the Rho-associated kinase (ROCK)

147 ing effect could be mediated by an adenosine A2 receptor via the protein kinase C (PKC) pathway.

148 d be inhibited by an antagonist of adenosine A(2) receptors, whereas, in contrast, (3) brief vascular

149 elated, but distinct, X-linked ectodysplasin-A2 receptor (XEDAR).